Guido Tricot

High Impact

Professor

University of Arkansas for Medical Sciences

faculty

Internal Med, College of Medicine

97 h-index 717 pubs 36,142 cited

Research Areas

Links

ORCID Lab Website Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Guido Tricot's research focuses on multiple myeloma, a hematologic malignancy. His work investigates the molecular mechanisms underlying disease progression, including the role of specific genes and proteins such as TRIP13, NEK2, and CST6. He has explored the genetic landscape of multiple myeloma, identifying cytogenetic alterations that contribute to its complexity and advancement. Additionally, Tricot's research addresses therapeutic strategies, with a focus on chimeric antigen receptor (CAR)-T cell therapy and bispecific antibodies targeting BCMA and CD24. His publications also examine disparities in access to these advanced treatments, highlighting geographic and racial inequities in clinical trials for multiple myeloma.

Tricot's extensive publication record, including over 700 publications and a h-index of 97, reflects his significant contributions to the field. He is recognized as a highly cited researcher. His laboratory maintains an active website and leads a research group, indicating ongoing research endeavors. Tricot collaborates extensively with colleagues at the University of Arkansas for Medical Sciences, including John D. Shaughnessy Jr., Clyde Bailey, Sharmilan Thanendrarajan, and Maurizio Zangari, with whom he has co-authored numerous publications.

Metrics

h-index: 97
Publications: 717
Citations: 36,142

Selected Publications

Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025) DOI
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025) DOI
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024) DOI
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024) DOI
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024) DOI
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024) DOI
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024) DOI
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023) DOI
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS (2023) DOI
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023) DOI
Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB. (2023) DOI
Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols. (2023) DOI
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma (2022) DOI
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022) DOI
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022) DOI

Grants & Funding

Gene expression profiling vs MRD assessment in Myeloma NIH Principal Investigator
UARK 2003-01, Stem Cell Mobilization and Transplantation of Proven and/or Predicted Poor Mobilizers with Mutliple Myeloma AnorMED, Inc. Principal Investigator
UARK 2003-01, Stem Cell Mobilization and Transplantation of Proven and/or Predicted Poor Mobilizers with Mutliple Myeloma AnorMED, Inc. Principal Investigator
UARK 2003-01, Stem Cell Mobilization and Transplantation of Proven and/or Predicted Poor Mobilizers with Mutliple Myeloma AnorMED, Inc. Principal Investigator